Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care.
Merjaneh, N; Young, J; Mangoli, A; Olsen, M; Setty, B; Lane, A; Nagarajan, R; Pressey, JG; Turpin, B.
Pediatric Blood and Cancer.
2022;
69.
GIST presenting as refractory iron-deficiency anaemia in paediatric patient.
Al Atrash, E; Abdullah, MF; Pressey, J; Mohan, S.
BMJ Case Reports.
2022;
15.
Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer.
Thapaliya, S; Gilligan, LA; Brady, SL; Anton, CG; Crotty, EJ; Nasser, MP; Geller, JI; Pressey, JG; Zhang, B; Dillman, JR; et al.
American Journal of Roentgenology.
2021;
217:1444-1451.
Novel ARHGAP23-FER fusion in a metastatic spindle cell-predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib.
Sadaf, A; Szabo, S; Ferguson, K; Sorger, JI; Sumegi, J; Bridge, JA; Pressey, JG.
Cancer.
2021;
127:4124-4130.
Active and Protected: Developing a "Safer Sex " Handout for Adolescents and Young Adults with Cancer.
McGrady, ME; Bredenberg, DL; Danziger-Isakov, L; Rios, J; Frias, O; West, MY; Fisher, P; Salloum, R; Pressey, JG; Norris, RE.
Journal of Adolescent and Young Adult Oncology.
2021;
10:351-354.
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Wang, Y; Pandey, RN; Roychoudhury, K; Milewski, D; Kalin, TV; Szabo, S; Pressey, JG; Hegde, RS.
Molecular Cancer Therapeutics.
2021;
20:803-815.
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski, D; Shukla, S; Gryder, BE; Pradhan, A; Donovan, J; Sudha, P; Vallabh, S; Pyros, A; Xu, Y; Barski, A; et al.
Oncogene.
2021;
40:2182-2199.
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Geller, JI; Pressey, JG; Smith, MA; Kudgus, RA; Cajaiba, M; Reid, JM; Hall, D; Barkauskas, DA; Voss, SD; Cho, SY; et al.
Cancer.
2020;
126:5303-5310.
Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma.
Lazow, MA; Johnson, SL; Johnson, ND; Breneman, JC; Dexheimer, PJ; Szabo, S; Pressey, JG.
JCO Precision Oncology.
2020;
4:498-504.